Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given
to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an
additional 86 patients will be enrolled. During this part of the study, the safety and
effectiveness will be evaluated.